David T. Paik
Stanford University, Vanderbilt University, Boston University, Phillips Exeter Academy
Research areas: Biochemistry, Genetics and Molecular Biology · Molecular Biology · Genetic Associations and Epidemiology · Pluripotent Stem Cells Research · Congenital heart defects research
0000-0002-7830-312X
About
Dr. David T. Paik is instructor working with Dr. Joseph Wu at Stanford Cardiovascular Institute. At Stanford, his focus is to utilize single-cell RNA-sequencing technology to elucidate patient-specific mechanisms of various cardiovascular diseases, characterize embryonic heart development, and optimize differentiation of iPSCs to subtypes of cardiovascular cells. Dr. Paik received his BA in Biochemistry and Molecular Biology at Boston University (2010) and PhD in Cell and Developmental Biology at Vanderbilt University (2015). At Vanderbilt, Dr. Paik was trained by Dr. Antonis Hatzopoulos to investigate the endogenous cardiac repair mechanisms in the adult heart following ischemic injury such as myocardial infarction. In particular, Dr. Paik focused on the role of Wnt signaling pathway on coronary vessel formation and plasticity of cardiac endothelial cells during cardiac tissue repair. During his PhD training, Dr. Paik completed HHMI/VUMC Certificate Program in Molecular Medicine, where he was supervised by his clinical mentor Dr. Douglas Sawyer to interact with congestive heart failure patients and to bridge clinical sciences with basic and translational cardiovascular research.
Employment
-
Stanford University Instructor
Education
-
Vanderbilt University Ph.D.2010 - 2015
-
Boston University B.A.2006 - 2010
- 2002 - 2006
Projects & Funding
-
Single-cell sequencing to elucidate endothelial cell-to-cardiomyocyte interaction during cardiac development American Heart Association2021 - 2023
-
Identifying Angiocrine Factors for Cardiomyocyte Maturation Using Single-Cell Sequencing National Heart Lung and Blood Institute2020 - 2022
Publications (37)
- Cross-cohort analysis of expression and splicing quantitative trait loci in TOPMed Save
- IGFBP2 Mediates Human iPSC-Cardiomyocyte Proliferation in a Cellular Contact-Dependent Manner Save
- SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant Save
- Adverse effects of air pollution‐derived fine particulate matter on cardiovascular homeostasis and disease Save
- Editorial commentary: Unraveling intricacies of cardiovascular disease at the single-cell resolution Save
- Editorial: Intercellular communication and crosstalk in cardiac development and disease. Save
- Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction. Save
- Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Save
- Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Save
- Endothelial-Myocardial Angiocrine Signaling in Heart Development. Save
- Single-Cell RNA Sequencing Unveils Unique Transcriptomic Signatures of Organ-Specific Endothelial Cells Save
- Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Save
- High-throughput Preparation of DNA, RNA, and Protein from Cryopreserved Human iPSCs for Multi-omics Analysis. Save
- Single-cell RNA sequencing in cardiovascular development, disease and medicine Save
- Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. Save
- An extracellular matrix paradox in myocardial scar formation Save
- Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction Save
- Wnt Activation and Reduced Cell-Cell Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes. Save
- Modeling Secondary Iron Overload Cardiomyopathy with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Save
- Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. Save